Lu and Luo et al. performed CRISPR screens in primary macrophages and identified lactic acid, PGE2, and GM-CSF as tumor-derived modulators of TAM polarization. Lactic acid and PGE2 cooperatively induced angiogenic programs while suppressing MHC-II expression, whereas GM-CSF promoted MHC-IIhi TAMs. Angiogenic TAMs were present in hypoxic regions, and MHC-IIhi TAMs were in normoxic areas, creating mutually exclusive spatial niches in the TME. Deletion of Adar, an RNA-editing enzyme, reshaped TAMs into an “interferon-stimulated gene” state associated with T cell mediated antitumor immunity.
Contributed by Shishir Pant
ABSTRACT: Tumor-associated macrophages (TAMs) display remarkable functional heterogeneity, yet the molecular mechanisms driving their diverse phenotypes remain elusive. Using CRISPR screens in primary macrophages, we identified tumor-derived factors, including lactic acid, PGE2, and GM-CSF, as key modulators of TAM polarization. These factors interact synergistically and antagonistically to shape distinct TAM phenotypes that are highly conserved across human cancers. Mechanistically, lactic acid and PGE2 jointly induce angiogenic gene programs while suppressing GM-CSF-driven MHC-II expression at the chromatin level, creating mutually exclusive distributions of proangiogenic and MHC-II+ TAMs, which are differentially localized to specific spatial niches in the tumor microenvironment. Furthermore, we showed that shifting TAMs to an interferon-responsive phenotype, triggered by Adar inactivation, significantly promotes the infiltration of effector CD8+ T cells through specific receptor-ligand interactions. These findings uncover a conserved mechanism of TAM polarization and offer insights into therapeutic strategies for TAM reprogramming to potentiate cancer immunotherapy.
Author Info: (1) Tsinghua University, Beijing, Beijing, China. (2) Peking University, Beijing, China. (3) Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China. (4) Tsinghua University, Be
Author Info: (1) Tsinghua University, Beijing, Beijing, China. (2) Peking University, Beijing, China. (3) Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China. (4) Tsinghua University, Beijing, Beijing, China. (5) Tsinghua University, Beijing, Beijing, China. (6) Peking University, Beijing, Beijing, China. (7) Zhongnan Hospital of Wuhan University, Wuhan, Hubei province, China. (8) Dana-Farber Cancer Institute, Boston, United States. (9) Tsinghua University, Beijing, Beijing, China.
